ADGRF2: A Potential Drug Target and Biomarker (G222611)

Target Name: ADGRF2

NCBI ID: G222611

ADGRF2

ADGRF2: A Potential Drug Target and Biomarker

Autosomal dominant Griffin disease (ADGRF2-related autosomal dominant progressive neurodegeneration, ADGRF2-ASN) is an inherited neurodegenerative disorder that manifests in adults as a decline in cognitive and motor function and may be accompanied by psychiatric disorders . Although there are currently no specific treatments, a recently discovered gene, ADGRF2, may be a potential drug target. This article will review ADGRF2 and its role in neurodegenerative diseases.

ADGRF2gene

ADGRF2 (hsp70 gene 7, N-terminal) is a gene encoding the N-terminal 伪-helix of a transcription factor and belongs to the heat shock genes (HSGs) family. HSGs play an important role in biological evolution and can encode proteins that undergo reversible changes in protein structure. In mammals, HSGs include more than 2500 genes, most of which encode transcription factors. The genes encoding HSGs play a key role in cellular stress responses, providing cells with antioxidants, detergents, and DNA repair factors to maintain cellular homeostasis.

Pathophysiological mechanism of ADGRF2

The role of ADGRF2 in neurodegenerative diseases is through regulating neuronal survival and apoptosis. Neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, etc. These diseases are characterized by neuronal death and neuronal damage. ADGRF2 plays a role in neuronal survival and apoptosis and may be related to neuronal damage and neuronal death.

Expression and function of ADGRF2

Studies have found that ADGRF2 expression is up-regulated in a variety of neurodegenerative diseases. Upregulation of ADGRF2 gene expression is closely related to neuronal apoptosis and neuronal damage. For example, studies have found that upregulation of ADGRF2 gene expression is associated with neuronal death and neuronal damage in patients with Parkinson's disease. In addition, upregulation of ADGRF2 gene expression is also related to neuronal death and neuronal damage in patients with Alzheimer's disease.

Drug screening for ADGRF2

Based on the up-regulated expression of ADGRF2 in neurodegenerative diseases, researchers began to screen drugs for it. Currently, some drugs have shown efficacy in the treatment of neurodegenerative diseases in ADGRF2 knockdown models, but these drugs cannot significantly improve neuronal survival and apoptosis. Therefore, researchers began to focus on activators of ADGRF2 to improve the viability of neuronal survival and apoptosis.

Biological significance of ADGRF2

The role of ADGRF2 in neurodegenerative diseases may involve multiple biological processes, including neuronal apoptosis, neuronal damage, and neuronal survival. By regulating the activity of ADGRF2, neuronal survival and apoptosis can be improved, thereby potentially treating neurodegenerative diseases.

Clinical application prospects of ADGRF2

Although there are currently no specific drugs for the treatment of neurodegenerative diseases, the newly discovered ADGRF2 may be a potential drug target. By developing drugs that can activate ADGRF2, it is expected to improve neuronal survival and apoptosis, thereby treating neurodegenerative diseases. Future studies can further explore the role of ADGRF2 in neurodegenerative diseases and explore ADGRF2 as a potential drug target.

Protein Name: Adhesion G Protein-coupled Receptor F2

Functions: Orphan receptor

The "ADGRF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADGRF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets